Effect of diode laser cyclophotocoagulation in treatment of patients with refractory glaucoma

Vladimir Čanadanović; Ljiljana Tušek-Lješević; Aleksandar Miljković; Sava Barišić; Tatjana Bedov; Nikola Babić

doi:10.2298/5123

Vladimir Čanadanović Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Ljiljana Tušek-Lješević Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
Aleksandar Miljković Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Sava Barišić Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
Tatjana Bedov Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Nikola Babić Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

DOI: https://doi.org/10.2298/5123

Keywords: ophthalmologic surgical procedures, glaucoma, laser coagulation, lasers, intraocular pressure, treatment outcome,

Abstract

Background/Aim. Refractory glaucoma is glaucoma resistant to conventional management (maximally tolerated medical therapy, one or more glaucoma surgeries) and glaucoma in cases of neovascularisation after panretinal photocoagulation or cryoablation. The aim of the study was to determine the intraocular pressure (IOP) lowering efficacy of transscleral diode laser cyclophotocoagulation (DCPC) treatment in the management of pain and IOP in patients with refractory glaucoma. Methods. This nonrandomized, retrospective study, included 95 patients (95 eyes) with refractory glaucoma treated at the University Eye Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia, between November 2007 and November 2012 in accordance with the established protocols (16–18 spots, 270°, up to 5J of energy). All the eyes were treated with transscleral DCPC (Iris Medical OcuLight SLx, Iridex Co, Mountain View, USA). Patient's symptoms, bests corrected visual acuity and IOP were recorded 7 days, and 1, 3 and 6 months after the DCPC treatment. Results. Out of 95 patients (95 eyes) enrolled in this study 24 (25.2%) were with primary (the group I), and 71 (74.5%) with secondary (the group II) glaucoma. The mean baseline IOP in these two groups was similar: 36.08 ± 8.39 mmHg for the first group and 37.36 ± 8.19 mmHg in the second group. Measurement of the mean IOP in the group I showed the following results: on the day 7 it was 13.96 ± 8.30 mmHg (62.1% decrease of the baseline value), on the day 30 it was 18.44 ± 8.85 mmHg (48.9% decrease regarding the baseline value), after 3 months it was 22.44 ± 7.36 mmHg (37.8% decrease regarding the baseline value), and after 6 months it was 25.92 ± 7.65 mmHg (28.2% decrease regarding the baseline value). Measurement of IOP in the group II showed the following results: on the day 7 it was 15.77 ± 9.73 mmHg (57.8% decrease of the baseline value), on the day 30 it was 20.14 ± 10.20 mmHg (46.1% decrease regarding the baseline value), after 3 months it was 23.46 ± 9.83 mmHg (37.2% decrease regarding the baseline value) and after 6 months it was 27.23 ± 9.87 mmHg (27.2% decrease regarding the baseline value). Pain was the main symptom in 70 (73.6%) patients before the treatment and it persisted in only 4 (4.2%) of our patients. Other complaints (burning, stinging, foreign body sensation) were experienced by 39 (41%) of the patients, postoperatively. A total of 52 (54.7%) patients had no complaints after the treatment. Conclusion. Our study confirmed that transscleral DCPC is a useful, effective and safe procedure with predictable amount of IOP decrease, which makes it the treatment of choice for refractory glaucoma.

References

Berlin MS. Miscallenous laser procedures including laser ciliary body therapy. In: Stamper R, Lieberman MF, Drake MV, editors. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. 8th ed. Philadelphia, PA: Mosby-Elsevier; 2009. p. 456−7.

Khalid M, Rafay A, Mirza J, Asim W, Muhammad T, Qazi A. Transscleral Diode Laser Cyclophotocoagulation for the Treatment of Refractory Glaucoma. Pak J Ophthalmol 2007; 23(4): 204−8.

Khomchik OV, Bol'shunov AV, Il'ina TS. Laser cyclodestructive procedures in glaucoma treatment. Vestn Oftalmol 2012; 128(3): 54−9. (Russian)

Subrata M, Ritu G, Jatin A. Diode laser cyclophotocoagulation. J Curr Glaucoma Pract 2009; 3(2):47-59.

van der Zypen E, England C, Fankhauser F, Kwasniewska S. The ef-fect of transscleral laser cyclophotocoagulation on rabbit ciliary body vascularization. Graefes Arch Clin Exp Ophthalmol 1989; 227(2): 172−9.

Schubert HD, Federman JL. A comparison of CW Nd: YAG contact transscleral cyclophotocoagulation with cyclocryopexy. Invest Ophthalmol Vis Sci 1989; 30(3): 536−42.

Liu G, Mizukawa A, Okisaka S. Mechanism of intraocular pressure decrease after contact transscleral continuous-wave Nd:YAG laser cyclophotocoagulation. Ophthalmic Res 1994; 26(2): 65−79.

Hennis HL, Stewart WC. Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma. Am J Oph-thalmol 1992; 113(1): 81−5.

Agarwal HC, Gupta V, Sihota R. Evaluation of contact versus non-contact diode laser cyclophotocoagulation for refractory glaucomas using similar energy settings. Clin Experiment Ophthalmol 2004; 32(1): 33−8.

Cantor LB, Nichols DA, Katz LJ, Moster MR, Poryzees E, Shields JA, et al. Neodymium-YAG transscleral cyclophotocoagulation. The role of pigmentation. Invest Ophthalmol Vis Sci 1989; 30(8): 1834−7.

Schubert HD, Agarwala A, Arbizo V. Changes in aqueous out-flow after in vitro neodymium: yttrium aluminum garnet laser cyclophotocoagulation. Invest Ophthalmol Vis Sci 1990; 31(9): 1834−8.

Morrison J, Pollack I. Cyclodestruction. In: Morisson J, Pollack I, editors. Glaucoma: Science and practice. New York: Thieme; 2003. p. 448−55.

Noureddin BN, Zein W, Haddad C, Ma'luf R, Bashshur Z. Diode laser transcleral cyclophotocoagulation for refractory glauco-ma: a 1 year follow-up of patients treated using an aggressive protocol. Eye (Lond) 2006; 20(3): 329−35.

Murphy CC, Burnett CA, Spry PG, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol 2003; 87(10): 1252−7.

Mastrobattista JM, Luntz M. Ciliary body ablation: where are we and how did we get here. Surv Ophthalmol 1996; 41(3): 193−213.

Benson MT, Nelson ME. Cyclocryotherapy: a review of cases over a 10-year period. Br J Ophthalmol 1990; 74(2): 103−5.

Schuman JS, Bellows AR, Shingleton BJ, Latina MA, Allingham RR, Belcher CD, et al. Contact transscleral Nd:YAG laser cyclopho-tocoagulation. Ophthalmology 1992; 99(7): 1089−95.

Ulbig MW, McHugh DA, McNaught AI, Hamilton AM. Clinical comparison of semiconductor diode versus neodymium: YAG non-contact cyclo photocoagulation. Br J Ophthalmol 1995; 79(6): 569−74.

Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Oph-thalmol 2007; 91(12): 1631−5.

Rosentreter A, Gaki S, Lappas A, Cursiefen C, Dietlein TS. Previous cyclodestruction is a risk factor for late-onset hypotony and suprachoroidal haemorrhage after glaucoma drainage device surgery. Br J Ophthalmol 2013; 97(6): 715−9.

Ataullah S, Biswas S, Artes PH, O'Donoghue E, Ridgway AE, Spencer AF. Long term results of diode laser cycloablation in complex glaucoma using the Zeiss Visulas II system. Br J Ophthalmol 2002; 86(1): 39−42.

Hawkins TA, Stewart WC. One-year results of semiconductor transscleral cyclophotocoagulation in patients with glaucoma. Arch Ophthalmol 1993; 111(4): 488−91.

Egbert PR, Fiadoyor S, Budenz DL, Dadzie P, Byrd S. Diode laser transscleral cyclophotocoagulation as a primary surgical treat-ment for primary open-angle glaucoma. Arch Ophthalmol 2001; 119(3): 345−50.

Kosoko O, Gaasterland DE, Pollack IP, Enger CL. Long-term out-come of initial ciliary ablation with contact diode laser trans-scleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology 1996; 103(8): 1294−302.